CS Paper Radar

Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy Using Temporal Deep Learning on DWI

Pablo García Marcos, Md. Tarequl Islam, Paula Puerta González, Guillermo Lorenzo, Héctor Gómez, Covadonga del Camino, Angel Rio-Alvarez, Víctor M. González

cs.AI ·submitted 2026-08-18 12:08 UTC · v1

Abstract

Early identification of non-responders to neoadjuvant chemotherapy (NACT) is crucial for timely treatment adaptation in breast cancer. However, many existing predictive models rely on multiparametric magnetic resonance imaging (MRI), late treatment time points, or extensive clinical data, which limits their applicability. This study proposes a deep learning framework for early prediction of pathological complete response (pCR) using only diffusion-weighted MRI (DW-MRI) acquired at baseline and after the first NACT cycle. This framework feeds cropped tumor-centered patches to an EfficientNet-based temporal model that directly learns tumor shape and local tissue characteristics without explicit radiomic feature engineering. The model, trained with 10-fold cross-validation, achieved an area under the receiver operating characteristic curve (AUC) of 0.90 for pCR prediction after one cycle, providing actionable information after a single treatment cycle while avoiding gadolinium administration and reducing dependence on heterogeneous clinical data. By focusing on the baseline-to-first-cycle window instead of later stages, the approach supports earlier escalation or de-escalation of NACT, and its exclusive reliance on DW-MRI facilitates protocol standardization, multi-centre deployment and privacy-preserving data sharing. These results demonstrate that DW-MRI-based deep learning on tumor-centered patches constitutes a minimally invasive, clinically deployable strategy for early pCR prediction, with direct implications for personalized treatment adaptation in neoadjuvant breast cancer therapy.

Closest papers

Nearest neighbours by meaning across the whole index.

Neoadjuvant chemotherapy response prediction using pretreatment diffusion and contrast-enhanced magnetic resonance imaging with clinical variables

cs.AI cs.CV ·2026-08-18 ·Pablo García Marcos, Paula Puerta González, Guillermo Lorenzo, Héctor Gómez, Covadonga del Camino +4 more
similarity 0.80
Abstract

Prediction of pathological complete response before neoadjuvant chemotherapy may facilitate more tailored therapeutic planning for breast cancer patients. This work proposes a deep-learning model for pretreatment data only, combining apparent diffusion coefficient maps, dynamic contrast-enhanced magnetic resonance imaging, and clinical variables. The study uses the public ACRIN 6698/I-SPY2 multicenter dataset. The architecture employs EfficientNet-B0 pretrained encoders for image feature extraction and late fusion with clinical information. Multiple clinical variables were evaluated, including age, race, histological type, HR/HER2 subtype, SBR grade, and maximum diameter. Only HR/HER2 subtype improved the average area under the receiver operating characteristic curve (AUC) and was retained in the final model. Using stratified five-fold cross-validation, standalone apparent diffusion coefficient maps achieved a mean AUC of 0.79, whereas dynamic contrast-enhanced magnetic resonance imaging achieved 0.74. Adding HR/HER2 subtype improved performance to 0.83 and 0.81, respectively. The final configuration, using both imaging modalities and HR/HER2 subtype, achieved an AUC of 0.86. These results support pretreatment multimodal learning for response prediction, although external validation is required before clinical use.

0.27

CoRe-WM: Conditioned Response-State World Modeling for Longitudinal Treatment-Response Prediction in Breast DCE-MRI

cs.CV ·2026-10-18 ·Lin Zhao, Bowen Chen, Qiaohui Gao, Shaowen Wan, Xiang Li +2 more
similarity 0.76
Abstract

Pathologic complete response (pCR) after neoadjuvant chemotherapy is a key prognostic indicator in aggressive breast cancer, yet existing prediction approaches either rely on pretreatment imaging alone, missing the patient's evolving response, or optimize multi-visit classifiers under direct outcome supervision, coupling representation learning with the clinical endpoint. We formulate longitudinal pCR prediction as a world-modeling problem and propose Conditioned Response-state World Modeling (CoRe-WM), which learns a latent state-transition model that predicts the next imaging state from the observed sequence. The transition function is conditioned on patient clinical profile and assigned therapy through additive shift and feature-wise modulation, enabling patient- and treatment-specific dynamics. A Factorized Response State pathway further decouples treatment-response dynamics from imaging appearance by encoding the structural prior that response manifests primarily in lesion morphology. After pretraining, all parameters are frozen and a linear readout predicts pCR at each clinical decision point. We evaluate CoRe-WM on I-SPY2 under five-fold cross-validation and assess cross-cohort transfer on I-SPY1. CoRe-WM achieves the highest discrimination among all evaluated methods at every prospective decision point, and demonstrates robust cross-cohort transfer. Ablation studies identify patient-profile conditioning and the factorized response pathway as the principal contributors. These results establish world-model-based representation learning as a promising framework for outcome prediction in oncology and beyond.

0.20

Physics-Informed Deep Learning in Oncology

cs.CE ·2026-10-13 ·Scindhiya Laxmi, Vivek S. Yadav, Ameya D. Jagtap
similarity 0.72
Abstract · 51 pages

Deep learning has enabled substantial advances in oncology, including cancer detection and diagnosis, medical image analysis, tumor characterization, treatment planning, response assessment, and outcome prediction. However, conventional data-driven models often require large annotated datasets, exhibit limited generalization across heterogeneous clinical settings, and lack explicit mechanisms for incorporating the physical, physiological, and biological principles underlying cancer development and treatment. Physics-informed deep learning (PIDL) integrates governing physical laws, mechanistic models, physiological constraints, and domain knowledge into deep learning frameworks, providing a principled approach for learning from sparse, noisy, and heterogeneous oncological data. This review presents a task-oriented synthesis of PIDL methods across oncology, encompassing neural networks, Kolmogorov-Arnold networks, convolutional and vision architectures, neural operators, generative models, and hybrid physics-data-driven frameworks. Their applications are examined across cancer detection and diagnosis, image reconstruction and analysis, tumor characterization, quantitative imaging, tumor progression, treatment response, radiation therapy, treatment planning, and multimodal clinical modeling. Based on the synthesized methodological and application-level evidence, we develop task-optimized PIDL workflows that align the clinical task with appropriate data representations, physical constraints, model architectures, and validation strategies. We further analyze key challenges, including physical-model fidelity, computational scalability, uncertainty quantification, domain generalization, standardized benchmarking, and clinical validation.

0.09

Heterogeneity-Aware Deep Learning for Tumour Classification from Multiparametric MRI

cs.CV ·2026-08-18 ·Yue Xia, Euijoon Ahn, Tian Xia, Yuan Yuan, Michael Fulham +1 more
similarity 0.71
Abstract

Intra-tumoural heterogeneity (ITH) reflects spatial variation in tumour biology and is an important determinant of tumour behaviour, prognosis, and treatment response. Radiomics and deep learning have shown promise for tumour classification from multiparametric MRI (mp-MRI), but radiomics relies on handcrafted features, while most deep learning methods use whole-tumour representations or manually defined sub-regions, limiting scalable modelling of tumour heterogeneity. We propose a Heterogeneity-Aware Deep Learning Classification (HA-DLC) framework that explicitly models imaging-derived tumour sub-regions for lesion-type diagnosis and molecular-status prediction. HA-DLC consists of: (1) a Heterogeneous Sub-region Generation (HSG) module that produces initial pseudo-labelled sub-regions via unsupervised clustering, followed by Cross-Patient Sub-region Alignment (CPSA), which maps cluster-derived regions to a shared label space using soft assignments; and (2) a Dual-Stream Feature Extraction (DSFE) module that integrates local heterogeneity-aware features with global tumour representations. Given the initial clustering masks, CPSA, segmentation, feature extraction, and classification are jointly optimized end-to-end using soft-target segmentation and classification objectives. We evaluate HA-DLC on the LLD-MMRI2023 liver lesion dataset and the RSNA-ASNR-MICCAI 2021 Radiogenomic Brain Tumour dataset. HA-DLC consistently outperforms state-of-the-art radiomics and deep learning baselines, demonstrating the value of cross-patient sub-region alignment and dual-stream heterogeneity modelling for tumour classification from mp-MRI.

0.26

Interpretable Deep Learning Models for Breast Cancer Diagnosis Using Medical Imaging

cs.CV cs.AI ·2026-10-27 ·Sami Alnawali, Muhammad Atif Saeed, Abdul Hadi, Azka Atiq, Akhtar Jamil +1 more
benchmark similarity 0.70
Abstract · 37 page, 45 Figures

Deep learning shows promise for breast cancer diagnosis, but limited interpretability hinders clinical adoption. We benchmark ten ImageNet-pretrained models (ResNet50, VGG19, InceptionV3, DenseNet121, Xception, MobileNetV2, EfficientNet, ConvNeXt, ViT, and Swin Transformer) for benign-versus-malignant classification on the BreakHis histopathology dataset using a patient-level split, and explain their predictions with Grad-CAM, LIME, Integrated Gradients, and LRP. DenseNet121 performed best, with 99.4% test accuracy and an AUC-ROC of 0.999, and significantly outperformed all other models (p < 0.001). Transformer-based models trailed the CNNs. The explanations consistently highlighted nuclei-rich and glandular regions of diagnostic relevance. Combining transfer learning with explainable AI can thus yield accurate, interpretable tools for breast cancer diagnosis.

0.19

Mammo-LIFE: Longitudinal Mammographic Imaging and Clinical Feature Enrichment for Post-Radiotherapy Outcome Prediction

cs.CV eess.IV ·2026-09-22 ·Farnoush Bayatmakou, Maryam Hosseini, Reza Taleei, Arash Mohammadi
similarity 0.70
Abstract

Recent advances in Artificial Intelligence (AI)-powered Computer-Aided Diagnosis (CAD) systems have substantially improved breast cancer screening, diagnosis, and prognosis. Comparatively, postradiotherapy outcome prediction using paired longitudinal mammograms has received considerably less attention. This is largely due to the limited availability of well-annotated longitudinal datasets. Longitudinal mammograms, coupled with paired pre- and post-treatment information, provide a unique opportunity to characterize treatment-induced breast tissue changes following radiotherapy. The resulting learned representations can serve as a valuable asset for advancing personalized radiotherapy planning and post-treatment management. In this context, we propose Mammo-LIFE, a patient-level multimodal framework for post-radiotherapy outcome prediction that combines longitudinal mammographic features with patient-level clinical variables. The imaging branch processes paired pre- and post-treatment mammograms acquired from the four standard views using a mammography-specific encoder adapted via Low-Rank Adaptation (LoRA). Within each view, preand post-treatment representations are explicitly compared through a longitudinal comparison module to capture treatment-related changes. The resulting view-level embeddings are then aggregated using learned view-attention pooling to form a unified patient-level mammographic representation. Selected clinical variables are subsequently combined with the image-derived prediction probability through a late-fusion strategy. To evaluate the effectiveness of combining paired longitudinal mammograms with clinical information, experiments were conducted on an in-house clinical cohort using patient-level stratified five-fold cross-validation.

0.26

Transcriptome-informed multi-modal AI for predicting neoadjuvant therapy response from breast cancer biopsies

cs.AI ·2026-10-02 ·Jungkyu Park, Dhruva Biswas, Joseph Cappadona, Cerise Tang, Ken G. Zeng +20 more
similarity 0.69
Abstract

Scarcity of labeled data limits development of deep learning biomarkers in oncology. We develop a two-stage AI model predicting pathological complete response (pCR) to neoadjuvant therapy in breast cancer. The first stage learns the transcriptome from histopathology using 8,742 patients across 32 cancer types, corroborated by pathologist review and spatial agreement with measured expression. This simplifies the second stage to predicting pCR from inferred expression and clinical variables. Developed using 1,080 patients (five cohorts) and evaluated in 1,412 patients (nine cohorts), the model achieves a pooled AUROC of 0.79 (95% CI, 0.73-0.85), discriminating responders within molecular subtypes. It outperforms histopathological biomarkers, remaining stable across intratumoral sampling and with minimal biopsy tissue. Ablations show transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays' gene selection constraints. These results indicate that biologically informed compression may generalize to data-sparse applications in precision oncology.

0.06

Feature Space Guidance for Breast Cancer Classification in DCE-MRI

cs.CV cs.AI ·2026-09-26 ·Benjamin Hamm, Yannick Kirchhoff, Maximilian Rokuss, Moritz Langenberg, Constantin Ulrich +4 more
top venuecode/data similarity 0.69
Abstract · 11 pages, 2 figures, 2 tables. Code: https://github.com/MIC-DKFZ/CURIAtor

Dynamic contrast enhanced breast MRI (DCE-MRI) is a powerful clinical tool for breast cancer detection, providing high resolution anatomical detail together with rich temporal contrast information. However, high dimensional 4D inputs, small lesions, and heterogeneous acquisition protocols across clinical sites hinder robust automated classification of healthy, benign, and malignant cases. To address these challenges, we propose a framework that dynamically analyzes latent representations to adapt to protocol-specific characteristics. Spatial variability is mitigated by reducing confounding background uptake and compensating for misalignment caused by deformable soft tissue. Additionally, relationships in the latent space across phases are leveraged to select the most informative temporal features, improving robustness to protocol-specific temporal variability. Finally, task specific discriminative features are promoted through large scale supervised lesion segmentation pretraining, which substantially enhances downstream finetuning. Evaluated under leave-one-center-out validation on the ODELIA dataset and the held-out AMBL cohort, the proposed framework substantially outperforms finetuned radiology foundation models and prior methods, improving mean AUROC by nearly 8 points and balanced accuracy by 4 points over the strongest baseline. Additionally, our method achieved first place in the MICCAI ODELIA Breast MRI Challenge 2025, further demonstrating its effectiveness for robust breast cancer classification. We publicly release our codebase under https://github.com/MIC-DKFZ/CURIAtor.

0.70